乳腺癌与遗传及性别相关结构和功能的重大异常
本文检索文献,分析8类性发育、性腺功能或性别结构异常人群中乳腺癌风险,包括特纳综合征、先天性低促性腺激素性性腺功能减退症、单纯性腺发育不全、克兰费尔特综合征、跨性别个体、完全性雄激素不敏感综合征及MRKH综合征。作者得出3点主要结论:存在Y染色体对乳腺癌发生具有保护作用;无月经周期时乳腺癌极少发生,终生月经周期数与乳腺癌风险强相关;MRKH综合征遗传女性中仅见1例乳腺癌报告。作者假设WNT4是MRKH遗传病因与MRKH综合征女性无乳腺癌之间的连接。
要点
- 存在Y染色体对乳腺癌发生具有保护作用,即使有女性大小乳房和女性水平雌激素。
- 无月经周期时乳腺癌极少发生,发病率与男性相当。
- 终生月经周期数与乳腺癌风险强相关;未暴露于孕酮的遗传女性乳腺癌风险很低,与男性相当。
核心结论
- 存在Y染色体对乳腺癌发生具有保护作用,即使有女性大小乳房和女性水平雌激素。
- 无月经周期时乳腺癌极少发生,发病率与男性相当;终生月经周期数与乳腺癌风险强相关。
- 未暴露于孕酮的遗传女性乳腺癌风险很低,与男性相当。
- MRKH综合征遗传女性中仅见1例乳腺癌报告,该例乳房正常、卵巢排卵且雌二醇和孕酮水平正常。
- 作者假设WNT4是MRKH遗传病因与MRKH综合征女性无乳腺癌之间的连接。
研究设计与样本
- 本文为文献检索,检索8类人群:特纳综合征(45, XO)女性;先天性低促性腺激素性性腺功能减退症和Kallmann综合征的男女;基因型和表型女性及基因型男性(Swyer综合征)的单纯性腺发育不全;克兰费尔特综合征(47, XXY)男性;男变女跨性别个体;女变男跨性别个体;基因型男性但表型女性且完全性雄激素不敏感综合征;MRKH综合征(苗勒管发育不全)女性。
主要发现
- 存在Y染色体对乳腺癌发生具有保护作用,即使有女性大小乳房和女性水平雌激素。
- 无月经周期时乳腺癌极少发生,发病率与男性相当。
- 终生月经周期数与乳腺癌风险强相关。
- 未暴露于孕酮的遗传女性乳腺癌风险很低,与男性相当。
- MRKH综合征遗传女性中仅见1例乳腺癌报告,该例乳房正常、卵巢排卵且雌二醇和孕酮水平正常。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We have searched the literature for information on the risk of breast cancer (BC) in relation to gender, breast development, and gonadal function in the following 8 populations: 1) females with the Turner syndrome (45, XO); 2) females and males with congenital hypogonadotropic hypogonadism and the Kallmann syndrome; 3) pure gonadal dysgenesis (PGD) in genotypic and phenotypic females and genotypic males (Swyer syndrome); 4) males with the Klinefelter syndrome (47, XXY); 5) male-to-female transgender individuals; 6) female-to-male transgender individuals; 7) genotypic males, but phenotypic females with the complete androgen insensitivity syndrome, and 8) females with Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome (müllerian agenesis). Based on this search, we have drawn 3 major conclusions. First, the presence of a Y chromosome protects against the development of BC, even when female-size breasts and female-level estrogens are present. Second, without menstrual cycles, BC hardly occurs with an incidence comparable to males. There is a strong correlation between the lifetime number of menstrual cycles and the risk of BC. In our populations the BC risk in genetic females not exposed to progesterone (P4) is very low and comparable to males. Third, BC has been reported only once in genetic females with MRKH syndrome who have normal breasts and ovulating ovaries with normal levels of estrogens and P4. We hypothesize that the oncogenic glycoprotein WNT family member 4 is the link between the genetic cause of MRKH and the absence of BC women with MRKH syndrome.
引用
- Coelingh Bennink HJT, Egberts JFM, Mol JA, et al. Breast Cancer and Major Deviations of Genetic and Gender-related Structures and Function. J Clin Endocrinol Metab. 2020. PMID: 32594127. doi:10.1210/clinem/dgaa404
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。